ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

STX Shield Therapeutics Plc

2.05
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.05 2.00 2.10 2.10 2.05 2.05 690,953 14:55:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.39 15.9M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.05p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £15.90 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.39.

Shield Therapeutics Share Discussion Threads

Showing 4851 to 4874 of 23400 messages
Chat Pages: Latest  204  203  202  201  200  199  198  197  196  195  194  193  Older
DateSubjectAuthorDiscuss
21/12/2019
17:21
Actually that presentation was given just under 5 weeks ago on the 19th November; on my first look I thought it was the 9th not the 19th so apologies. Nevertheless a lot could have happened in the last 5 weeks so I wouldn't rule out an announcement next week.
nobbygnome
20/12/2019
15:22
That talk was the beginning of November so about 6 weeks ago. It is still possible for us to get a deal next week but no drama if it takes into the New Year. I have slightly increased my spreadbet position this afternoon and will keep adding if it drifts down.
nobbygnome
20/12/2019
15:11
If the deal timescale is now being referred to as ‘how long is a piece of string’ then it doesn’t sound like it’ll be this year. Why would he say that if it was imminent or inline with previous commitments. I feel it may be well into Q1 hence the share price softening a bit this week. I don’t see much downside whilst we wait and if it’s a great deal then no one will care too much
siriusbizness
20/12/2019
14:02
Should be http
crankyman
20/12/2019
13:29
Can't connect.
montyhedge
20/12/2019
08:18
Still working on the US deal. European launches now expected 2021.
crankyman
20/12/2019
08:02
This is new: hxxps://youtu.be/j7haj75OTSI
crankyman
19/12/2019
16:01
So today the price moved down to 178p/180p on fairly low volume, then someone bought 25k shares at 184p and this did not push the price up?!
secret investor
19/12/2019
06:54
Did a post ref that interview some weeks back
best1467
19/12/2019
05:47
Yes it’s previous. Just not seen it on here before. Doesn’t matter when posted, just interesting to the follow up data
peachie 74
18/12/2019
23:06
Oh, thought it was from today, should put dates on these videos
ny boy
18/12/2019
22:42
This is old. It's from October. The Medical Director talking about the long term follow up data. Sorry to bust up the party.
crankyman
18/12/2019
22:22
Was that out today?
nobbygnome
18/12/2019
22:02
Good find peachie!

Looks like all is hunky dory

Hold and wait for the US commercialization deal now

ny boy
18/12/2019
21:10
Bloody link won’t work !
Great proactive investors video about showing the efficacy head to head with Ferinject after a year.

peachie 74
18/12/2019
21:09
hxxps://youtu.be/W6qTUxrAArc
peachie 74
18/12/2019
13:04
Think people are starting to look for negatives that don’t really exist Keep The Faith Tevas appeal for me and from what the board have Commented is a complete noNe issue
best1467
18/12/2019
11:21
NY Boy et al - There seems an assumption from STX that TEVA’s appeal will fail, but what are the potential senaria and financial consequences for STX if TEVA’s appeal does not end in failure?

And what impact could the appeal case in progress have on terms for the US and China deals, especially the size of any upfront payments?

If the financial impact is thought to be significant, would any US licensee delay signing until the appeal issue is resolved or make payments conditional or demand a clawback clause?

Could these factors and the lack of a STX response submission to date be a drag on completing the US deal?

borromini1
18/12/2019
11:01
Just a reminder that this only refers to patents after 2027 from memory. So this is not a short term issue and we won’t get any result for months yet.
nobbygnome
17/12/2019
15:18
That’s probably focusing the mind at the moment
crankyman
17/12/2019
12:46
Meanwhile I have been checking the European Patent Office to see how the TEVA Appeal is going, latest

13.08.2019
Teva Statement setting out grounds of appeal

20.08.2019
EPO notification that any reply from the Proprietor (STX),must be filed within 4 months of this date, actually they say 4 months + 10 days so allowing for holidays that should probably no later than 02.01.2020

04.12.2019
Composition of the Appeal Board who will hear the Appeal

The Application no EP2668175

Nb.They say they do not take responsibility for the complete accuracy of this information, so everyone take note!

You can register on the EPO web site to receive email alerts on this Appeal, which I have done

www.register.epo.org

ny boy
17/12/2019
11:07
Finncap are moving the price up and down at a whim! They certainly seem to control the price and are often on both the bid and the offer at the same time. Those pesky MM games....
nobbygnome
17/12/2019
10:45
This could be another IMMMTFBFrom highs to single digits
iamgreat1
17/12/2019
08:46
Big pharma is definitely better. This isn’t orphan oncology. But I think a big company with a significant OTC business would be better. Ultimately, ferric maltol is a nutritional aid. It’s not a medicine per se. The product sits between nutritional supplements and medicine. It could own the OTC market and that market could be enormous but it needs to go there with huge marketing and distributional reach. OTC iron sales are about 30 times the unit sales of IV. Getting even 5% of those would be massive even if the margin would shrink considerably. It’s where it will go eventually.
crankyman
Chat Pages: Latest  204  203  202  201  200  199  198  197  196  195  194  193  Older